Bartolotta E, Acquafredda A, Evain-Brion D, Job J C
Arch Fr Pediatr. 1987 Mar;44(3):181-3.
The effect of bromocriptine 7.5 mg/day for 8 to 14 months on bone maturation has been studied in 33 excessively tall adolescents (25 females and 8 males aged 11 to 16 years, at pubertal stages P2 - P3), using comparatively the atlas of Greulich and Pyle and the RUS method of Tanner and Whitehouse. With the Greulich and Pyle evaluation, bone age was very significantly increased during treatment: p less than 0.001 in females, p less than 0.01 in males. The RUS method gave significantly greater evaluation of bone age (p less than 0.001), so that the treatment-induced acceleration of bone maturation was less significant: p less than 0.01 in females, NS in males. These data confirm that bromocriptine in constitutionally tall adolescents acts mainly through an increase of pubertal bone maturation. Moreover they point out once again the difficulties and discrepancies of height prediction.
对33名身材过高的青少年(25名女性和8名男性,年龄11至16岁,青春期阶段为P2 - P3)进行了研究,观察每天服用7.5毫克溴隐亭,持续8至14个月对骨骼成熟的影响,采用Greulich和Pyle图谱以及Tanner和Whitehouse的RUS方法进行对比评估。根据Greulich和Pyle评估,治疗期间骨龄显著增加:女性p < 0.001,男性p < 0.01。RUS方法得出的骨龄评估值显著更高(p < 0.001),因此治疗引起的骨骼成熟加速不太显著:女性p < 0.01,男性无显著差异。这些数据证实,溴隐亭在体质性身材高大的青少年中主要通过增加青春期骨骼成熟发挥作用。此外,它们再次指出了身高预测的困难和差异。